Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Investigational New Drugs|June 21, 2017
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse eventFrancesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Cancers|October 15, 2014
MET and Small-Cell Lung CancerFrancesco Gelsomino, Giulio Rossi, Marcello Tiseo
Immunotherapy|January 11, 2023
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITYEmanuel Raschi, Francesca Comito, Francesco Massari, et al.
Expert Review of Anticancer Therapy|April 21, 2009
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtypeMarcello Tiseo, Marco Bartolotti, Francesco Gelsomino, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2021
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2021
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER databaseAndrea De Giglio, Alessandro Di Federico, Francesco Gelsomino, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2009
Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case reportMarcello Tiseo, Francesco Gelsomino, Marco Bartolotti, et al.
World Journal of Virology|November 1, 2013
Innate host responses to West Nile virus: Implications for central nervous system immunopathologyGiada Rossini, Maria Paola Landini, Francesco Gelsomino, et al.
Critical Reviews in Oncology/Hematology|March 23, 2021
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Current Oncology Reports|August 28, 2021
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)Andrea De Giglio, Alessandro Di Federico, Giacomo Nuvola, et al.
Pageof 11